FDA Approves First Gene Therapy for Sanfilippo A
Regulatory clearance for Fayuvi establishes clinical proof for targeted pediatric adeno-associated vectors, setting clear boundaries for how rare genetic conditions are diagnosed and managed.
The United States Food and Drug Administration approved Fayuvi, known generically as rebisufligene etisparvovec-hopf, as the first targeted treatment for pediatric patients with mucopolysaccharidosis type IIIA. The progressive lysosomal storage disorder, colloquially termed Sanfilippo syndrome type A, leads to neurodegeneration and childhood mortality due to an inability to break down heparan sulfate.
Fayuvi uses an adeno-associated virus vector to introduce a functional copy of the SGSH gene directly to patient cells. This single-dose transfer restores the missing sulfamidase enzyme, halting the toxic build-up of metabolic byproducts across the central nervous system. Regulatory approval was granted after clinical trials confirmed stable enzymatic activity and a slowing of neurological decline in treated children.
If you are evaluating expanded carrier screenings during family planning, ensure your clinical team orders comprehensive sequence analysis rather than basic commercial panels that frequently omit rare lysosomal variants.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.